Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Observational × surufatinib × Clear all

Status

Sponsor Class

Study Type

Interventional 44 Observational 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumor Grade 3 1

Interventions

Surveys and Questionnaires 440 Blood Specimen Collection 334 Surgical Procedures, Operative 121 Radiotherapy 117 Interviews as Topic 113 Drug Therapy 103 Observation 97 Magnetic Resonance Spectroscopy 89 Biopsy 86 Specimen Handling 60 Data Collection 60 Neoadjuvant Therapy 55 Magnetic Resonance Imaging 55 Immunohistochemistry 51 Immune Checkpoint Inhibitors 49 Watchful Waiting 45 Positron Emission Tomography Computed Tomography 40 Bevacizumab 40 Liquid Biopsy 38 Ultrasonography 37 Radiosurgery 37 pembrolizumab 35 Therapeutics 35 Gene Expression Profiling 35 Immunotherapy 33 Hematologic Tests 32 Focus Groups 32 Colonoscopy 32 Tomography, X-Ray Computed 29 Polymerase Chain Reaction 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon ⚡